首页> 美国卫生研究院文献>Materials >Functionalized Large-Pore Mesoporous Silica Microparticles for Gefitinib and Doxorubicin Codelivery
【2h】

Functionalized Large-Pore Mesoporous Silica Microparticles for Gefitinib and Doxorubicin Codelivery

机译:吉非替尼和阿霉素代码传递的功能化大孔介孔二氧化硅微粒

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Large-pore coralline mesoporous silica microparticles (CMS) were synthesized using the triblock polymer PEG-b-PEO-b-PEG and a hydrothermal method. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) revealed the coralline morphology of the fabricated materials. The Brunauer–Emmett–Teller (BET) method and the Barrett–Joyner–Halenda (BJH) model confirmed the existence of large pores (20 nm) and of a tremendous specific surface area (663.865 m2·g−1) and pore volume (0.365 cm3·g−1). A novel pH-sensitive multiamine-chain carboxyl-functionalized coralline mesoporous silica material (CMS–(NH)3–COOH) was obtained via a facile “grafting-to” approach. X-ray photoelectron spectroscopy (XPS) and Fourier-transform infrared spectroscopy (FT-IR) validated the effective interfacial functionalization of CMS with carboxyl and multiamine chains. The encapsulation and release behavior of the dual drug (gefitinib (GB) and doxorubicin (DOX)) was also investigated. It was found that CMS–(NH)3–COOH allows rapid encapsulation with a high loading capacity of 47.36% for GB and 26.74% for DOX. Furthermore, the release profiles reveal that CMS–(NH)3–COOH can preferably control the release of DOX and GB. The accumulative release rates of DOX and GB were 32.03% and 13.66%, respectively, at a low pH (pH 5.0), while they reduced to 8.45% and 4.83% at pH 7.4. Moreover, all of the modified silica nanoparticles exhibited a high biocompatibility with a low cytotoxicity. In particular, the cytotoxicity of both of these two drugs was remarkably reduced after being encapsulated. CMS–(NH)3–COOH@GB@DOX showed tremendously synergistic effects of the dual drug in the antiproliferation and apoptosis of A549 human cancer cells in vitro.
机译:使用三嵌段聚合物PEG-b-PEO-b-PEG和水热法合成了大孔珊瑚中孔二氧化硅微粒(CMS)。扫描电子显微镜(SEM)和透射电子显微镜(TEM)揭示了所制造材料的珊瑚线形态。 Brunauer-Emmett-Teller(BET)方法和Barrett-Joyner-Halenda(BJH)模型证实存在大孔(20 nm)和巨大的比表面积(663.865 m 2 ·· g -1 )和孔体积(0.365 cm 3 ·g -1 )。通过一种简便的“接枝”方法获得了一种新型的pH敏感的多胺链羧基官能化珊瑚碱介孔二氧化硅材料(CMS-(NH)3-COOH)。 X射线光电子能谱(XPS)和傅里叶变换红外光谱(FT-IR)验证了具有羧基和多胺链的CMS的有效界面功能。还研究了双重药物(吉非替尼(GB)和阿霉素(DOX))的包封和释放行为。发现CMS–(NH)3–COOH可以快速封装,GB的装载量为47.36%,DOX的装载量为26.74%。此外,释放曲线表明,CMS-(NH)3-COOH可以较好地控制DOX和GB的释放。在低pH值(pH 5.0)下,DOX和GB的累积释放率分别为32.03%和13.66%,而在pH 7.4下它们分别降低至8.45%和4.83%。而且,所有改性的二氧化硅纳米颗粒均表现出高生物相容性和低细胞毒性。特别地,这两种药物在包封后均显着降低了细胞毒性。 CMS–(NH)3–COOH @ GB @ DOX显示了双重药物在体外对A549人癌细胞的抗增殖和凋亡的巨大协同作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号